News
Media
PodcastsCase Based Peer PerspectivesClinical Forum InsightsInsightsInvestigator PerspectivesMedical World NewsPeer ExchangePeers & PerspectivesVideos
Conferences
Conference CoverageConference Listing
Publications
Contemporary OB/GYN® JournalDigital Supplements
More
CME/CE
Resources
Physician Fact SheetsInteractive ToolsSponsored MediaSponsored ResourcesSupplements and Featured Publications
About
Partnerships

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • About
  • Partnerships
  • Breast Health
  • COVID-19
  • Cervical Health
  • Contraception
  • Curbside Consults
  • Dermatology
  • Drug Pipeline News
  • Endometriosis
  • Genetic Testing
  • Gynecology
    • Gynecologic Oncology
  • Imaging
    • Fetal Imaging
    • Abnormal Obstetrical Ultrasound
    • MRI
    • Ultrasound
    • Women's Imaging
    • Breast Imaging
    • Women's Ultrasound
  • Infertility
  • LARC
  • Legally Speaking
  • Life Transitions
  • Malpractice
  • Menopause
  • Mental Health
  • Noninvasive Prenatal Testing
  • Obstetrics
  • Opinion
  • Osteoporosis
  • Pediatrics
  • Practice Management
  • Pregnancy and Birth
  • Sexual Health
  • Sexually Transmitted Infections
  • Surgery
  • Technology
  • Urology
  • Uterine Fibroids
  • Vulvovaginal Disease
  • Well Woman
Advertisement

Angela C. Weyand, MD

Advertisement

Articles by Angela C. Weyand, MD

VTE

Progestins for AUB in women at risk of VTE

ByEmma Lawrence, MD,Elisabeth Quint, MD,Angela C. Weyand, MD
February 10th 2020

These four patient cases can help improve your decision-making about the best hormonal regimen for this population.

Advertisement

Latest Updated Articles

  • VTE
    Progestins for AUB in women at risk of VTE

    Published: February 10th 2020 | Updated:



Advertisement
Advertisement

Trending on Contemporary OB/GYN

1

FDA approves 5-year use for etonogestrel implant 68 mg contraceptive

2

Barbara Levy, MD, reacts to HRSA's updated cervical cancer guidelines

3

Prenatal factors and offspring risk of adult multiple sclerosis

4

RE104 30 mg demonstrates efficacy and safety in new phase 2 data for postpartum depression

5

Breaking down biases against user-administered injectable contraceptives with Jennifer Karlin, MD

  • Advertise
  • Contact Us
  • Job Board
  • Terms of Use
  • Privacy Policy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us